In the BioFINDER pilot cohort, CSF NPTX2 levels showed a significant decrease in patients with AD, compared to CU (Figure 3A), with a FC in AD of 0.82 (CI95% = 0.67–0.99, p = 0.006). The gene discussed is NPTX2; the disease is Alzheimer disease.